ANN ARBOR, Mich. Researchers at the University of Michigans Michigan Medicine and three other medical centers were awarded a total of $7 million from the National Heart, Lung, and Blood Institute (NHBLI) to study convalescent plasma in reducing symptoms of COVID-19 in patients with mild cases, Michigan Medicine announced Thursday.
The other medical centers awarded funding are the University of Pittsburgh, Medical University of South Carolina and Stanford Medicine.
As part of NHBLIs initiative, the Clinical Trial of COVID-19 Convalescent Plasma of Outpatients (C3PO), the institute plans to study whether preventing a mild case from becoming severe can come from passive immunization.
Convalescent plasma contains antibodies that can bind to the virus that causes COVID-19, neutralizing it.
A press release from Michigan Medicine said convalescent plasma can be used as a treatment for hospital patients with severe to life-threatening COVID-19, which is the passive immunization.